Related references
Note: Only part of the references are listed.Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs
Sangwoo Park et al.
ACS NANO (2020)
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State
Kyungho Jang et al.
CLINICAL THERAPEUTICS (2020)
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naive patients with type 2 diabetes: initial triple study
Soo Lim et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men
Seol Ju Moon et al.
CLINICAL THERAPEUTICS (2020)
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks
Sin Gon Kim et al.
DIABETES OBESITY & METABOLISM (2020)
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity
Ruth F. Rocha et al.
BIOORGANIC CHEMISTRY (2020)
The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: A comparison with other thiazolidinediones
Min Jeong Kwon et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Thiazolidinediones: the Forgotten Diabetes Medications
Harold E. Lebovitz
CURRENT DIABETES REPORTS (2019)
Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice
G. Kim et al.
INTERNATIONAL JOURNAL OF OBESITY (2018)
Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
Sorim Choung et al.
PPAR RESEARCH (2018)
Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPAR gamma
Jun Young Jang et al.
SCIENTIFIC REPORTS (2018)
Therapeutic Effects of Targeted PPAR. Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo
Jah Yeon Choi et al.
THERANOSTICS (2018)
Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
Na-Rae Shin et al.
FRONTIERS IN PHARMACOLOGY (2018)
The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
Yu Seol Lee et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes
J. -Y. Lee et al.
DIABETES & METABOLISM (2018)
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
Yong-ho Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Soo Lim et al.
DIABETES & METABOLISM JOURNAL (2017)
Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
Min A. Lee et al.
SCIENTIFIC REPORTS (2017)
Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis
Soo Lim et al.
ATHEROSCLEROSIS (2015)
Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects
Choon O. K. Kim et al.
CLINICAL THERAPEUTICS (2015)
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension
S-M Jin et al.
DIABETES OBESITY & METABOLISM (2015)
Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study
Sun Hwa Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
Raymond E. Soccio et al.
CELL METABOLISM (2014)
Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects
Min Kyu Park et al.
CLINICAL DRUG INVESTIGATION (2014)
Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers
Eun Sil Oh et al.
CLINICAL THERAPEUTICS (2014)
CKD-501, a novel selective PPAR. agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks
Kyoung-Sik Moon et al.
JOURNAL OF APPLIED TOXICOLOGY (2014)
Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
Sin Gon Kim et al.
PLOS ONE (2014)
Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects
Donghoon Shin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
Chin-Hsiao Tseng et al.
JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS (2012)
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study
G. Bolli et al.
DIABETES OBESITY & METABOLISM (2008)
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial
BH Charbonnel et al.
DIABETIC MEDICINE (2005)
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation
AA Ali et al.
ENDOCRINOLOGY (2005)
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
SE Kahn
DIABETOLOGIA (2003)
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
S Rosenblatt et al.
CORONARY ARTERY DISEASE (2001)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Share Paper
